Quality of life · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: headache · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) showed no clear difference in adverse effect Headache compared with other medical therapy (low certainty).
1 finding from 1 review
Adverse effect Breakthrough bleeding/spotting · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) may leads to lower adverse effect Breakthrough bleeding/spotting compared with other medical therapy (low certainty).
1 finding from 1 review
Menstrual blood loss PBAC score · women with heavy menstrual bleeding
2 findings from 1 review
Satisfaction · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) may leads to lower satisfaction compared with other medical therapy (low certainty).
1 finding from 1 review
Days of bleeding · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibody response (geometric mean titre) · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Invasive cervical, vaginal, vulval, anal, or penile cancer · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
High‐grade cervical, vulval, vaginal, penile, or anal intraepithelial neoplasia · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall systemic events and general symptoms · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to 5‐year · 9‐ to 14‐year‐old females and males
It is very uncertain whether two doses of HPV vaccine with longer interval changes serious adverse events at up to 5‐year compared with two doses of HPV vaccine with shorter interval (very low certainty).
1 finding from 1 review
Mortality at up to 5‐year · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Clinical and harms outcomes* · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth or ongoing pregnancy · women undergoing pituitary suppression in assisted reproduction
Long protocol: administration of GnRHa for two showed no clear difference in live birth and ongoing pregnancies per woman randomised compared with three weeks before stimulation (low certainty).
1 finding from 1 review
Clinical pregnancy rate · women undergoing pituitary suppression in assisted reproduction
Long protocol: administration of GnRHa for two showed no clear difference in clinical pregnancies per woman randomised compared with three weeks before stimulation (low certainty).
1 finding from 1 review
Repetition of SH at post‐intervention · self‐harm in adults
Comparison 2.4: DBT prolonged exposure protocol showed no clear difference in repetition of SH at post‐intervention compared with TAU or another comparator (moderate certainty).
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in ocular surface staining at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in ocular surface staining at 1‐month (with actual compared with placebo or no treatment (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review